Vanguard Group
TCON

Vanguard Group’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Vanguard Group’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,139
Closed -$113K – 4455
2024
Q1 		$113K Hold
13,139
– – ﹤0.01% 4232
2023
Q4 		$46K Sell
13,139
-17,848
-58% -$62.8K ﹤0.01% 4380
2023
Q3 		$110K Sell
30,987
-6,167
-17% -$33.1K ﹤0.01% 4338
2023
Q2 		$216K Buy
37,154
+7,603
+26% +$139K ﹤0.01% 4302
2023
Q1 		$1.12M Hold
29,551
– – ﹤0.01% 3880
2022
Q4 		$881K Buy
29,551
+17
+0.1% +$514 ﹤0.01% 3949
2022
Q3 		$986K Hold
29,534
– – ﹤0.01% 4005
2022
Q2 		$1.18M Hold
29,534
– – ﹤0.01% 4023
2022
Q1 		$1.55M Sell
29,534
-4,997
-14% -$251K ﹤0.01% 4058
2021
Q4 		$1.91M Sell
34,531
-212
-0.6% -$13.5K ﹤0.01% 4057
2021
Q3 		$2.69M Buy
34,743
+291
+0.8% +$24.6K ﹤0.01% 3963
2021
Q2 		$4.47M Sell
34,452
-209
-0.6% -$28.9K ﹤0.01% 3660
2021
Q1 		$5.71M Buy
34,661
+19,094
+123% +$3.68M ﹤0.01% 3460
2020
Q4 		$3.64M Buy
15,567
+14,840
+2,041% +$2.07M ﹤0.01% 3491
2020
Q3 		$75K Hold
727
– – ﹤0.01% 4041
2020
Q2 		$29K Hold
727
– – ﹤0.01% 4052
2020
Q1 		$25K Hold
727
– – ﹤0.01% 4040
2019
Q4 		$34K Sell
727
-3,330
-82% -$219K ﹤0.01% 4065
2019
Q3 		$362K Sell
4,057
-342
-8% -$35.1K ﹤0.01% 3871
2019
Q2 		$598K Sell
4,399
-1,030
-19% -$163K ﹤0.01% 3798
2019
Q1 		$1.49M Buy
5,429
+643
+13% +$139K ﹤0.01% 3530
2018
Q4 		$603K Buy
4,786
+1,408
+42% +$382K ﹤0.01% 3693
2018
Q3 		$1.39M Buy
3,378
+5
+0.1% +$2.31K ﹤0.01% 3637
2018
Q2 		$1.82M Buy
3,373
+1,988
+144% +$1.06M ﹤0.01% 3528
2018
Q1 		$637K Buy
1,385
+217
+19% +$118K ﹤0.01% 3741
2017
Q4 		$783K Buy
1,168
+382
+49% +$231K ﹤0.01% 3664
2017
Q3 		$495K Buy
786
+87
+12% +$45.3K ﹤0.01% 3752
2017
Q2 		$336K Sell
699
-200
-22% -$122K ﹤0.01% 3801
2017
Q1 		$674K Buy
899
+78
+10% +$69.9K ﹤0.01% 3683
2016
Q4 		$805K Sell
821
-144
-15% -$165K ﹤0.01% 3627
2016
Q3 		$1.3M Buy
965
+12
+1% +$13.5K ﹤0.01% 3510
2016
Q2 		$835K Buy
953
+16
+2% +$21.2K ﹤0.01% 3653
2016
Q1 		$1.31M Buy
937
+198
+27% +$282K ﹤0.01% 3520
2015
Q4 		$1.37M Buy
739
+60
+9% +$120K ﹤0.01% 3527
2015
Q3 		$1.33M Buy
679
+577
+566% +$1.35M ﹤0.01% 3543
2015
Q2 		$231K Buy
+102
New +$239K ﹤0.01% 4023

Other funds holding TCON

GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return

Vanguard Group's TCON Position: Q2 2024 in Review

Vanguard Group sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 13,139 shares — an estimated $113K sold.

Vanguard Group first reported a position in TCON in Q2 2015 and held it in 36 quarters. The position peaked at $5.71M in Q1 2021. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.

  • Vanguard Group reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 13,139 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $113K.
  • Vanguard Group first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2015 and held it in 36 quarters.
  • Vanguard Group's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $5.71M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.